News
Third Generation Targeted Therapy for ROS1-Positive NSCLC
The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in preclinical studies against nearly all known mutations in the ALK and ROS1 genes that lead to resistance to crizotinib treatment. Moreover, lorlatinib crosses the blood-brain barrier, offering hope for patients with CNS metastases. The results of a clinical evaluation of the efficacy and safety of lorlatinib in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) were published in The Lancet Oncology.
Key Role of HRCT in Diagnosing Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is often an unjustly overlooked disease. The truth is that it is a…
The Choice of Incontinence Aids Matters − But How Not to Get Lost Among Them?
Despite significant advances in medicine, a large number of patients still struggle with…
Prevalence of Diabetics Among Patients with COVID-19 and the Impact of DM on the Course of Infection
Italian authors published the results of a meta-analysis of studies at the end of March, assessing…
Idiopathic Pulmonary Fibrosis: Rare Disease with Severe Prognosis
Idiopathic pulmonary fibrosis (IPF) represents a diagnostic and therapeutic challenge. This rare…
Impact of Empagliflozin on the Risk of Cardiovascular Death and Need for Hospitalization Due to Heart Failure
In the EMPA-REG OUTCOME study, empagliflozin reduced the risk of cardiovascular death and the number...
Domestic application of biological asthma treatment improves quality of life and reduces doctor visits
The benefits of the possibility of home application of omalizumab, a monoclonal antibody indicated…
Comparison of Efficacy and Safety of Unsaponifiable Soy and Avocado Oil and Chondroitin Sulfate in the Treatment of Knee Osteoarthritis
Osteoarthritis is the most common joint disease in adult patients, with its prevalence increasing…
The Presence of COPD Worsens the Course of COVID-19 – Results of Epidemiological Studies
Among the at-risk populations during the current COVID-19 pandemic are older individuals and those…
Are All Patients Really Suitable for Thromboprophylaxis Treated This Way?
A study published this year aimed to assess how often the risk of VTE is assessed in routine…